Web Exclusives

These revenue cycle tips improve your financial performance and free up time to focus on what really matters — your oncology patients. Read Article ›

On December 2, 2019, Merck announced that the FDA has granted priority review for its supplemental biologics license application for the anti–PD-1 agent pembrolizumab (Keytruda). If approved, the drug would be indicated as monotherapy to treat patients with Bacillus Calmette-Guerin–unresponsive, high-risk, non–muscle-invasive bladder cancer who are ineligible for or have decided not to undergo cystectomy. Read Article ›

Supporting patients with financial toxicity requires a human touch. Here are some ways financial counselors help patients and improve revenue cycle in community oncology. Read Article ›

Ovarian cancer not only exacts a high mortality rate, but also affects the physical, mental, and financial health of those diagnosed with the disease. Read Article ›

Epidemiologic studies reveal population-based disparities in ovarian cancer morbidity and mortality rates. Read Article ›

Genetic, menstrual, and other factors have been associated with increased risk of ovarian cancer. Read Article ›

Current screening practices for ovarian cancer continue to result in late-stage diagnoses with consequent poor prognoses. Read Article ›

  • Calquence Receives FDA Approval for the Treatment of Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
  • Despite Some Positive Trends, Report Confirms Lung Cancer Remains the Deadliest Form of Cancer
Read Article ›

On November 15, 2019, the FDA approved crizanlizumab (Adakveo; Novartis) to reduce the frequency of vaso-occlusive crises (VOCs) in adults and pediatric patients aged ≥16 years with sickle-cell disease. Read Article ›

3 ways to optimize financial counseling operations so you can reduce financial stress for your patients and improve your oncology practice’s revenue cycle. Read Article ›

  • Teva Will Resume Production of Vincristine in Response to Shortage
  • FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
  • FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma
Read Article ›

It’s important for community oncology practices to understand how and when they will be affected by Appropriate Use Criteria (AUC). Here’s what you need to know. Read Article ›

Page 1 of 4

Subscribe to
Oncology Practice Management

Stay up to date with oncology news & updates by subscribing to recieve the free OPM print publications or weekly e‑Newsletter.

I'd like to recieve: